These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 31196374)
41. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. von Pawel J; Bordoni R; Satouchi M; Fehrenbacher L; Cobo M; Han JY; Hida T; Moro-Sibilot D; Conkling P; Gandara DR; Rittmeyer A; Gandhi M; Yu W; Matheny C; Patel H; Sandler A; Ballinger M; Kowanetz M; Park K Eur J Cancer; 2019 Jan; 107():124-132. PubMed ID: 30562710 [TBL] [Abstract][Full Text] [Related]
42. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823 [TBL] [Abstract][Full Text] [Related]
43. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Facchinetti F; Bordi P; Leonetti A; Buti S; Tiseo M Drug Des Devel Ther; 2018; 12():2857-2873. PubMed ID: 30237696 [TBL] [Abstract][Full Text] [Related]
44. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400 [TBL] [Abstract][Full Text] [Related]
45. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328 [TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions. Qin Q; Li B J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226 [TBL] [Abstract][Full Text] [Related]
48. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210 [TBL] [Abstract][Full Text] [Related]
49. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Shen X; Zhao B BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221 [TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
52. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
53. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180 [TBL] [Abstract][Full Text] [Related]
54. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898 [TBL] [Abstract][Full Text] [Related]
55. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab. Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191 [TBL] [Abstract][Full Text] [Related]
56. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential. Armstrong SA; Liu SV Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697 [TBL] [Abstract][Full Text] [Related]
57. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. Villaruz LC; Socinski MA Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? Dempke WC; Sellmann L; Fenchel K; Edvardsen K Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995 [TBL] [Abstract][Full Text] [Related]
59. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. Tartarone A; Roviello G; Lerose R; Roudi R; Aieta M; Zoppoli P Future Oncol; 2019 Jul; 15(20):2423-2433. PubMed ID: 31237152 [No Abstract] [Full Text] [Related]
60. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]